Literature DB >> 19418962

Improvement in chemical and physical stability of fluvastatin drug through hydrogen bonding interactions with different polymer matrices.

G Z Papageorgiou1, S Papadimitriou, E Karavas, E Georgarakis, A Docoslis, D Bikiaris.   

Abstract

Solid dispersions of Fluvastatin with polyvinylpyrrolidone (PVP), eudragit RS100 (Eud), and chitosan (CS) as drug carrier matrices, were prepared using different techniques in order to evaluate their effect on Fluvastatin stability during storage. The characterization of the three different systems was performed with the use of differential scanning calorimetry (DSC) and wide angle X-ray diffractometry (WAXD). It was revealed that amorphization of the drug occurred in all of the solid dispersions of Fluvastatin as a result of drug dissolution into polymer matrices and due to physical interactions (hydrogen bonding) between the polymer matrix and Fluvastatin. This was established through the use of FTIR spectroscopy. SEM and micro-Raman spectroscopy showed that Fluvastatin was interspersed to the polymer matrices in the form of molecular dispersion and nanodispersion, too. The finding that completely different polymer matrices, used here as drug carriers, produce completely different dissolution profiles for each one of the solid dispersions, suggests that each matrix follows a different drug release mechanism. Hydrogen bonding interactions as in the case of CS/Fluva solid dispersions lead to controlled release profiles. All formulations were subjected to accelerated aging in order to evaluate Fluvastatin stability. From by-products analysis it was found that Fluvastatin is very unstable during storage and anti-isomer as well as lactones are the main formed by-products. On the other hand, solid dispersions due to the evolved interactions of their reactive groups with Fluvastatin provide a sufficient physical and chemical stability. The extent of interactions seems to play the most important role in the drug stabilization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19418962     DOI: 10.2174/156720109787048230

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  4 in total

1.  Preparation and evaluation of enteric coated tablets of hot-melt extruded lansoprazole.

Authors:  Bader B Alsulays; Vijay Kulkarni; Sultan M Alshehri; Bjad K Almutairy; Eman A Ashour; Joseph T Morott; Abdullah S Alshetaili; Jun-Bom Park; Roshan V Tiwari; Michael A Repka
Journal:  Drug Dev Ind Pharm       Date:  2016-08-21       Impact factor: 3.225

2.  Effect of sodium bicarbonate as a pharmaceutical formulation excipient on the interaction of fluvastatin with membrane phospholipids.

Authors:  Germain Larocque; Alexandre A Arnold; Etienne Chartrand; Yves Mouget; Isabelle Marcotte
Journal:  Eur Biophys J       Date:  2010-08-27       Impact factor: 1.733

3.  Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin.

Authors:  Jun Li; Min Yang; Wen-Rong Xu
Journal:  Drug Des Devel Ther       Date:  2018-10-23       Impact factor: 4.162

4.  Solid-state characterization of lacidipine/PVP K(29/32) solid dispersion primed by solvent co-evaporation.

Authors:  Amit Mukharya; Shivang Chaudhary; Niyaz Mansuri; Arun K Misra
Journal:  Int J Pharm Investig       Date:  2012-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.